A small cancer-procedure tools maker could see a lift as more doctors use its catheter across both the planning and treatment steps, now that insurance billing makes those steps easier to get paid for. The bigger question is whether new uses outside the liver catch on fast enough to cover rising spending before losses and manufacturing headaches become a drag.Read more
TriSalus is betting that its pressure-based drug delivery tools can become a go-to option across many tumor and vascular procedures, helped by reimbursement support and growing doctor adoption. The big question is whether it can expand beyond its core use cases fast enough to offset rising sales costs and manufacturing complexity.Read more
TriSalus aims to make certain tumor treatments easier to deliver through catheter-based procedures, but the big question is whether enough doctors will adopt it fast enough for the business to scale. New uses, supportive reimbursement, and an aging patient base could help, yet training, competition, and reliance on partners could slow progress and keep cash needs high.Read more
No trending discussion available.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
